News and Trends 17 Jan 2023
Ascletis phase I COVID trial progressing
Ascletis Pharma Inc. has announced the dosing of four healthy subjects in its multiple-dose escalation phase I clinical trial of oral 3-chymotrypsin like protease (3CLpro) inhibitor ASC11 in combination with…